

Andrew Henderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3424506/publications.pdf>

Version: 2024-02-01

16
papers

380
citations

1307594

7
h-index

940533

16
g-index

16
all docs

16
docs citations

16
times ranked

594
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Infections by OXA-48-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	105
2	Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study. Clinical Infectious Diseases, 2021, 73, e3842-e3850.	5.8	82
3	Whole genome analysis of cephalosporin-resistant Escherichia coli from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27. Journal of Antimicrobial Chemotherapy, 2018, 73, 634-642.	3.0	56
4	Control of healthcare- and community-associated MRSA: recent progress and persisting challenges. British Medical Bulletin, 2018, 125, 25-41.	6.9	30
5	Comparative Genomics and Antimicrobial Resistance Profiling of <i>Elizabethkingia</i> Isolates Reveal Nosocomial Transmission and <i>In Vitro</i> Susceptibility to Fluoroquinolones, Tetracyclines, and Trimethoprim-Sulfamethoxazole. Journal of Clinical Microbiology, 2020, 58, .	3.9	27
6	Oral cephalosporin and β -lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 2384-2393.	3.0	26
7	An unusual skin lesion caused by <i>Lasiodiplodia theobromae</i> . Medical Mycology Case Reports, 2015, 8, 44-46.	1.3	17
8	Epidemiology of extended-spectrum β -lactamase and metallo- β -lactamase-producing <i>Escherichia coli</i> in South Asia. Future Microbiology, 2021, 16, 521-535.	2.0	7
9	Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials, 2021, 22, 889.	1.6	6
10	A survey of the antibiotic prescribing practices of doctors in an Australian Emergency Department. Infection, Disease and Health, 2018, 23, 67-73.	1.1	5
11	A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens. Clinical Microbiology and Infection, 2021, 27, 1746-1753.	6.0	5
12	<i>In Vitro</i> Activity of Cefotetan against ESBL-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Bloodstream Isolates from the MERINO Trial. Microbiology Spectrum, 2021, 9, e0022621.	3.0	5
13	Activity of temocillin against third-generation cephalosporin-resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bloodstream isolates from a clinical trial. JAC-Antimicrobial Resistance, 2022, 4, dlab192.	2.1	4
14	Misidentification of <i>Brucella suis</i> as <i>Ochrobactrum anthropi</i> in a Patient with Septic Arthritis. Clinical Microbiology Newsletter, 2016, 38, 66-68.	0.7	2
15	Editorial: Oral antivirals for mild-moderate COVID-19: a panacea or a logistical and clinical conundrum?. Australian Prescriber, 2022, 45, 67-68.	1.0	2
16	A real time auditing and feedback program of peripheral intravenous cannulas with a focus on improving rates of redundancy. Infection, Disease and Health, 2017, 22, 36-42.	1.1	1